DE Burlo Group Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DE Burlo Group Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,690 shares of the biopharmaceutical company's stock after acquiring an additional 600 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.2% of DE Burlo Group Inc.'s holdings, making the stock its 26th biggest holding. DE Burlo Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $9,133,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the last quarter. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company's stock valued at $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Putnam Investments LLC lifted its position in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company's stock valued at $1,063,377,000 after purchasing an additional 24,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after buying an additional 184,561 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Joseph J. Larosa sold 1,866 shares of the business's stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares of the company's stock, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,270 shares of company stock worth $10,695,833. Company insiders own 7.48% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on REGN. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an "overweight" rating in a research note on Friday, August 23rd. Canaccord Genuity Group reissued a "buy" rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Barclays boosted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Trading Up 0.9 %

Regeneron Pharmaceuticals stock traded up $8.81 during mid-day trading on Thursday, reaching $1,039.96. 682,712 shares of the company traded hands, compared to its average volume of 483,553. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The firm has a market capitalization of $114.59 billion, a price-to-earnings ratio of 30.60, a P/E/G ratio of 3.72 and a beta of 0.12. The firm's 50 day moving average price is $1,129.87 and its 200 day moving average price is $1,033.99.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts' expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.